Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados OAK (1) BJID (1) Autor CAO, Shinuo (1) Campos,P. (1) Canfield,C. J. (1) Clendenes,M. (1) Hutchinson,D. B. A. (1) IGARASHI, Ikuo (1) KAMYINGKIRD, Ketsarin (1) Llanos-Cuentas,A. (1) MASATANI, Tatsunori (1) MOUMOUNI, Paul Franck Adjou (1) MOUSA, Ahmed Abd El Moniem (1) NISHIKAWA, Yoshifumi (1) TERKAWI, Mohamad Alaa (1) VUDRIKO, Patrick (1) XUAN, Xuenan (1) 五十嵐, 郁男 (1) 玄, 学南 (1) 西川, 義文 (1) Mais... Palavra-chave Atovaquone (2) Babesia bovis (1) Chemotherapeutic target agent (1) Chloroquine resistance (1) Dihydroorotate dehydrogenase (1) Leflunomide (1) Malarone (1) Peru (1) Proguanil (1) Mais... Tipo do documento Info:eu-repo/semantics/article (1) Ano 2014 (1) 2001 (1) País Brazil (1) Japan (1) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfadoxine for treatment of acute Plasmodium falciparum malaria in Peru BJID Llanos-Cuentas,A.; Campos,P.; Clendenes,M.; Canfield,C. J.; Hutchinson,D. B. A.. The efficacy and safety of a fixed-dose combination of atovaquone and proguanil hydrochloride (MalaroneTM) were compared with chloroquine or pyrimethamine/sulfadoxine in patients with acute falciparum malaria in northern Peru. Patients were initially randomized to receive 1,000 mg atovaquone and 400 mg proguanil hydrochloride daily for 3 days (n=15) or 1,500 mg chloroquine (base) over a 3 day period (n=14) (phase 1). The cure rate with chloroquine was lower than expected and patients were subsequently randomized to receive a single dose of 75 mg pyrimethamine and 1,500 mg sulfadoxine (n=9) or atovaquone/proguanil as before (n=5) (phase 2). In phase 1, atovaquone/proguanil was significantly more effective than chloroquine (cure rate 100% [14/14] versus 8%... Tipo: Info:eu-repo/semantics/article Palavras-chave: Malarone; Atovaquone; Proguanil; Chloroquine resistance; Peru. Ano: 2001 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702001000200004 Babesia bovis Dihydroorotate Dehydrogenase (BboDHODH) is a Novel Molecular Target of Drug for Bovine Babesiosis OAK KAMYINGKIRD, Ketsarin; CAO, Shinuo; MASATANI, Tatsunori; MOUMOUNI, Paul Franck Adjou; VUDRIKO, Patrick; MOUSA, Ahmed Abd El Moniem; TERKAWI, Mohamad Alaa; NISHIKAWA, Yoshifumi; IGARASHI, Ikuo; XUAN, Xuenan; 西川, 義文; 五十嵐, 郁男; 玄, 学南. The emergence of drug resistance and adverse side effects of current bovine babesiosis treatment suggest that the search of new drug targets and development of safer and effective compounds are required. This study focuses on dihydroorotate dehydrogenase (DHODH), the fourth enzyme of pyrimidine biosynthesis pathway as a potential drug target for bovine babesiosis. Recombinant Babesia bovis DHODH protein (rBboDHODH) was produced in Escherichia coli and used for characterization and measurement of enzymatic activity. Furthermore, the effects of DHODH inhibitors were evaluated in vitro. The recombinant B. bovis DHODH histidine fusion protein (rBboDHODH) had 42.4-kDa molecular weight and exhibited a specific activity of 475.7 ± 245 Unit/mg, a Km = 276.2 µM for... Palavras-chave: Atovaquone; Babesia bovis; Chemotherapeutic target agent; Dihydroorotate dehydrogenase; Leflunomide. Ano: 2014 URL: http://ir.obihiro.ac.jp/dspace/handle/10322/3918 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco